Form 4: vTv Therapeutics Inc. Announces Exchange Agreement with Baker Bros. Funds

vTv Therapeutics Inc. executed an exchange agreement with Baker Bros. funds, swapping common stock for prefunded warrants.

Summary

• On March 5, 2024, vTv Therapeutics Inc. entered into an exchange agreement with 667, L.P. and Baker Brothers Life Sciences, L.P.
• The agreement involved the exchange of 4,776 and 52,881 shares of Class A common stock for 4,780 and 52,925 prefunded warrants, respectively.
• The prefunded warrants have an exercise price of $0.01 per share and no expiration date.
• The warrants are exercisable on a 1-for-1 basis into common stock, subject to a beneficial ownership limitation of 4.99%, which can be increased to 19.99% with a 61-day notice.
• Dr. Raymond Cheong, an employee of Baker Bros. Advisors LP, was appointed as a director of vTv Therapeutics Inc. on February 27, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document describes a financial transaction (stock for warrants) and a board appointment, without expressing strong positive or negative views. The potential for future capital is a slight positive, but the dilution risk is a slight negative.

Positives

• The exchange agreement provides vTv Therapeutics with potential future capital through the exercise of the prefunded warrants.
• The prefunded warrants have a low exercise price of $0.01, making them attractive to holders.
• The warrants have no expiration date, providing flexibility to the holders.
• The appointment of Dr. Raymond Cheong to the board could bring valuable expertise to vTv Therapeutics.

Risks

• The beneficial ownership limitation on the warrants could restrict the extent to which the holders can exercise them.
• The exercise of the warrants could dilute existing shareholders' equity.
• The value of the warrants is dependent on the future performance of vTv Therapeutics' common stock.

Future Outlook

The document does not contain specific forward-looking statements beyond the implications of the warrant exchange.

Industry Context

This type of transaction, involving the exchange of stock for warrants, is a fairly common financing strategy in the biotech industry, particularly for companies seeking to raise capital while managing dilution.

Comparison to Industry Standards

• Similar transactions can be seen with companies like BioCryst Pharmaceuticals and Ligand Pharmaceuticals, where warrant offerings were used to secure funding from institutional investors.
• The warrant exercise price of $0.01 is relatively low, suggesting the warrants were issued at a time when the company's stock price was significantly depressed or as part of a restructuring agreement.
• The beneficial ownership limitations are common in such agreements to prevent hostile takeovers or undue influence by a single investor.

Management Changes

Related Party Transactions

• The exchange agreement with Baker Bros. funds, where Baker Bros. has a significant ownership stake, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution if the prefunded warrants are exercised.
• The company's financial position could be strengthened by the potential capital infusion from the warrant exercise.
• The appointment of Dr. Raymond Cheong could impact the company's strategic direction.

Next Steps

• The holders of the prefunded warrants may choose to exercise them in the future, subject to the beneficial ownership limitation.
• vTv Therapeutics will need to manage the potential dilution from the exercise of the warrants.
• Monitor the impact of Dr. Raymond Cheong's appointment on the company's strategy and performance.

Key Dates